Schizophrenia Clinical Trials in Anaheim, California

8 studies are recruiting for schizophrenia in Anaheim, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Local Institution - 0190, Anaheim, California
    Locations
    59 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07686263 on ClinicalTrials.gov

  2. 52-week Open Label Safety-Tolerability Study

    Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Advanced Research Center, Anaheim, California
    Locations
    23 in total
    Run by
    LB Pharmaceuticals Inc.

    See if you can join NCT07369154 on ClinicalTrials.gov

  3. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

    Stage
    Phase 3
    Ages
    13 to 17
    Site
    Advanced Research Center Inc., Anaheim, California
    Locations
    38 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07288567 on ClinicalTrials.gov

  4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Advanced Research Center, Inc, Anaheim, California
    Locations
    64 in total
    Run by
    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

  5. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

    The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

    Stage
    Phase 3
    Ages
    5 to 17
    Site
    Advanced Research Center Inc., Anaheim, California
    Locations
    91 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07424404 on ClinicalTrials.gov

  6. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage
    Not phased
    Ages
    18 and older
    Site
    Pamoja Advanced Nursing Practice, Anaheim, California
    Locations
    55 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

  7. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

    This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

    Stage
    Phase 1
    Ages
    10 to 17
    Site
    BioXcel Clinical Research Site, Anaheim, California
    Locations
    5 in total
    Run by
    BioXcel Therapeutics Inc

    See if you can join NCT05025605 on ClinicalTrials.gov

  8. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Anaheim, California
    Locations
    21 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.